Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients
Open Access
- 20 January 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 100 (3), 487-493
- https://doi.org/10.1038/sj.bjc.6604885
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric CancerDigestive Diseases and Sciences, 2006
- Effects of HER2 overexpression on cell signaling networks governing proliferation and migrationMolecular Systems Biology, 2006
- The effectiveness of trastuzumab (Herceptin) combined with chemotherapy for gastric carcinoma with overexpression of the c-erbB-2 proteinGastric Cancer, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerThe New England Journal of Medicine, 2005
- Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumabAnnals of Oncology, 2005
- Coamplified and overexpressed genes at ERBB2 locus in gastric cancerInternational Journal of Cancer, 2004
- Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER‐2 in 426 breast carcinomas from 37 centresThe Journal of Pathology, 2003
- Protein Overexpression and Gene Amplification of c-erbB-2 in Pulmonary Carcinomas: A Comparative Immunohistochemical and Fluorescence In Situ Hybridization StudyLaboratory Investigation, 2001
- Extended lymphadenectomy is associated with a survival benefit for node-negative gastric cancerJournal of Gastrointestinal Surgery, 1998
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989